$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000112170216000076 Filed on August 08, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$188.0K	$744.0K
YoY Change	-74.73%	6.44%
Cost Of Revenue	$121.0K	$90.00K
YoY Change	34.44%	-78.57%
Gross Profit	$67.00K	$654.0K
YoY Change	-89.76%	134.41%
Gross Profit Margin	35.64%	87.9%
Selling, General & Admin	$1.149M	$2.464M
YoY Change	-53.37%	-7.54%
% of Gross Profit	1714.93%	376.76%
Research & Development	$1.550M	-$560.0K
YoY Change	-376.79%	-112.79%
% of Gross Profit	2313.43%	-85.63%
Depreciation & Amortization	$150.0K	$40.00K
YoY Change	275.0%	-71.43%
% of Gross Profit	223.88%	6.12%
Operating Expenses	$1.149M	$2.464M
YoY Change	-53.37%	-7.54%
Operating Profit	-$2.508M	-$6.129M
YoY Change	-59.08%	-9.36%
Interest Expense	$1.000K	$1.000K
YoY Change	0.0%	-133.33%
% of Operating Profit
Other Income/Expense, Net	$1.000K	$56.00K
YoY Change	-98.21%	1300.0%
Pretax Income	-$2.510M	-$380.0K
YoY Change	560.53%	-94.38%
Income Tax
% Of Pretax Income
Net Earnings	-$3.200M	-$6.073M
YoY Change	-47.31%	-16.06%
Net Earnings / Revenue	-1702.13%	-816.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$45.71M	-$86.71M
COMMON SHARES
Basic Shares Outstanding	27.84M shares	135.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.700M	$22.70M
YoY Change	-83.7%	312.73%
Cash & Equivalents	$3.708M	$22.71M
Short-Term Investments
Other Short-Term Assets	$1.100M	$1.600M
YoY Change	-31.25%	128.57%
Inventory	$396.0K	$600.0K
Prepaid Expenses
Receivables	$310.0K	$600.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.661M	$25.50M
YoY Change	-77.8%	152.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.577M	$743.0K
YoY Change	246.84%	23.83%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$717.0K	$700.0K
YoY Change	2.43%	0.0%
Total Long-Term Assets	$3.726M	$1.400M
YoY Change	166.14%	7.69%
TOTAL ASSETS
Total Short-Term Assets	$5.661M	$25.50M
Total Long-Term Assets	$3.726M	$1.400M
Total Assets	$9.387M	$26.90M
YoY Change	-65.1%	135.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.467M	$400.0K
YoY Change	266.75%	0.0%
Accrued Expenses	$1.701M	$3.184M
YoY Change	-46.58%	-0.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.050M	$3.800M
YoY Change	6.58%	-13.64%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.195M	$200.0K
YoY Change	497.5%	0.0%
Total Long-Term Liabilities	$1.195M	$200.0K
YoY Change	497.5%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.050M	$3.800M
Total Long-Term Liabilities	$1.195M	$200.0K
Total Liabilities	$5.245M	$4.000M
YoY Change	31.13%	-11.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$335.4M
YoY Change
Common Stock	$339.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.142M	$23.00M
YoY Change
Total Liabilities & Shareholders Equity	$9.387M	$26.90M
YoY Change	-65.1%	135.96%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$3.200M	-$6.073M
YoY Change	-47.31%	-16.06%
Depreciation, Depletion And Amortization	$150.0K	$40.00K
YoY Change	275.0%	-71.43%
Cash From Operating Activities	-$1.090M	-$5.470M
YoY Change	-80.07%	12.09%
INVESTING ACTIVITIES
Capital Expenditures	-$230.0K	-$80.00K
YoY Change	187.5%
Acquisitions
YoY Change
Other Investing Activities	$30.00K	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$200.0K	-$80.00K
YoY Change	150.0%	-101.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-270.0K	15.00M
YoY Change	-101.8%
NET CHANGE
Cash From Operating Activities	-1.090M	-5.470M
Cash From Investing Activities	-200.0K	-80.00K
Cash From Financing Activities	-270.0K	15.00M
Net Change In Cash	-1.560M	9.450M
YoY Change	-116.51%	389.64%
FREE CASH FLOW
Cash From Operating Activities	-$1.090M	-$5.470M
Capital Expenditures	-$230.0K	-$80.00K
Free Cash Flow	-$860.0K	-$5.390M
YoY Change	-84.04%	10.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27844260	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
CY2015Q4	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	465000	USD
CY2016Q2	mblx	Accrued Commercial Manufacturing Current AccruedCommercialManufacturingCurrent	13000	USD
	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	218000	USD
	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	232000	USD
CY2015Q2	mblx	Class Of Warrant Or Right Expiration Term ClassOfWarrantOrRightExpirationTerm	P4Y
CY2016Q2	mblx	Contractual Commitment Periodic Payment Obligation Service Fee ContractualCommitmentPeriodicPaymentObligationServiceFee	520	USD
CY2015Q2	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4319000	USD
	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	8244000	USD
CY2016Q2	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4289000	USD
	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	8621000	USD
	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	0	USD
	mblx	Increase Decrease In Deferred Rent And Long Term Liabilities IncreaseDecreaseInDeferredRentAndLongTermLiabilities	-150000	USD
	mblx	Lease Incentive Paidby Lessor LeaseIncentivePaidbyLessor	0	USD
	mblx	Lease Incentive Paidby Lessor LeaseIncentivePaidbyLessor	1332000	USD
CY2015Q2	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	161000	USD
	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	282000	USD
CY2016Q2	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	2431000	USD
	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	2628000	USD
CY2016Q2	mblx	Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments Operatingleaseslandlordreimbforleaseimprovementsadditionalpayments	444	USD
CY2016Q2	mblx	Operatingleaseslandlordreimbursementforleaseimprovements Operatingleaseslandlordreimbursementforleaseimprovements	889	USD
	mblx	Period Over Which Capital Resources Are Not Sufficient To Fund Planned Operations PeriodOverWhichCapitalResourcesAreNotSufficientToFundPlannedOperations	P12M
	mblx	Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
	mblx	Private Placement Issuance Costs Incurred During Noncashor Partial Noncash Transaction PrivatePlacementIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction	0	USD
CY2015Q4	mblx	Stock Purchase Agreement Default Stock Price Trigger StockPurchaseAgreementDefaultStockPriceTrigger	0.50
CY2015Q2	mblx	Unit Price UnitPrice	0.125
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	120000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1467000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	238000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	310000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3513000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1701000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	431000	USD
CY2016Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	370000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-72000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-78000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	338580000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	339391000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-517000	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2766191	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1939771	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5596537	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5815619	shares
CY2016Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	30000	sqft
CY2015Q4	us-gaap	Assets Assets	17088000	USD
CY2016Q2	us-gaap	Assets Assets	9387000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	15344000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	5661000	USD
CY2015Q2	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	178	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	301000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20046000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22707000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12269000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3708000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12269000	USD
CY2016Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3708000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.98
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22530322	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26981214	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22530322	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26981214	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	136000000	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23000000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	273000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	278000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6074000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11922000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3200000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9702000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	90000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	174000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	121000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	238000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	6873000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	13348000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	6023000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	13199000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	272000	USD
CY2015Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	51000	USD
CY2016Q2	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	58000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	277000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	882000	USD
CY2015Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	38885000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2015Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	146000	USD
CY2016Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	28000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-6000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2114000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	595000	USD
CY2015Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	31000	USD
CY2016Q2	us-gaap	Incentive To Lessee IncentiveToLessee	1322	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-165000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1273000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	94000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	72000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2141000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	99000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	605000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-22000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-118000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-31000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	875000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1043000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	307000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-74000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-47000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2000	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	328000	USD
CY2016Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	325000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	379000	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	396000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	51000	USD
CY2016Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	71000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016Q2	us-gaap	Investments And Cash InvestmentsAndCash	3708000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	4060000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	5245000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17088000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9387000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3910000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4050000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	2661000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-8561000	USD
CY2015Q2	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-209000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-665000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12129000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7890000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6073000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11916000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3198000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9696000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	56000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	43000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	32000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11959000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3230000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6129000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9731000	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	185138	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	784983	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	724505	USD
CY2016Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	7346256	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	503000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	723000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	714000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	717000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	150000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1195000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	55000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	USD
CY2015Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	297000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	-274000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	209000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	389000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1668000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	622000	USD
	us-gaap	Prepayment Fees On Advances Net PrepaymentFeesOnAdvancesNet	167	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	14703000	USD
CY2015Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	15000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2015Q2	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	31000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	905000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2577000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	494000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	494000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	125000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	432000	USD
CY2016Q2	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	45
CY2016Q2	us-gaap	Restructuring Charges RestructuringCharges	4000	USD
CY2016Q2	us-gaap	Restructuring Reserve Accelerated Depreciation RestructuringReserveAcceleratedDepreciation	600	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-325753000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-335449000	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	470000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	922000	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	188000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	345000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	113000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	185000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	174000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	495000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	744000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1389000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2793000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	3468000	USD
CY2016Q2	us-gaap	Security Deposit SecurityDeposit	307	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2464000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4930000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1613000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4340000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	894000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	901000	USD
CY2015Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	300000	shares
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	305000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	0	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13028000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	4142000	USD
CY2015Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1667
CY2015Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	150000	USD
CY2016Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	103000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23117539	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22838511	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27717447	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27542376	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company’s cash equivalents are invested solely in money market funds.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001121702-16-000076-index-headers.html	Edgar Link	pending
0001121702-16-000076-index.html	Edgar Link	pending
0001121702-16-000076.txt	Edgar Link	pending
0001121702-16-000076-xbrl.zip	Edgar Link	pending
ex-311x20160630.htm	Edgar Link	pending
ex-312x20160630.htm	Edgar Link	pending
ex-321x20160630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mblx-20160630.xml	Edgar Link	completed
mblx-20160630.xsd	Edgar Link	pending
mblx-20160630x10q.htm	Edgar Link	pending
mblx-20160630_cal.xml	Edgar Link	unprocessable
mblx-20160630_def.xml	Edgar Link	unprocessable
mblx-20160630_lab.xml	Edgar Link	unprocessable
mblx-20160630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2016 Q2 Form 10-Q Financial Statement

#000112170216000076 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2016 Q2 Form 10-Q Financial Statement

#000112170216000076 Filed on August 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq